Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 31, 2026

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

Data-driven computational modeling of CAR-T cell function.

Viren Shah1, Justin A Womack1, Katie Palen2

  • 1Department of Biomedical Engineering, Medical College of Wisconsin, Milwaukee, WI, United States.

Frontiers in Immunology
|May 29, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biocompatible Glycoconjugation Enables Sensitive In Vivo Cell Tracking by PET/CT.

Journal of medicinal chemistry·2026
Same author

Oncometabolite signatures from tumor-stroma crosstalk as potential non-invasive biomarkers.

Cell death discovery·2026
Same author

AMD3100 modulates the secretome responses of human Mesenchymal Stromal Cells but not their inhibitory effect on T cell proliferation.

Scientific reports·2026
Same author

Autofluorescence imaging reveals the impact of cryopreservation on T cell metabolism and activation response.

Molecular therapy. Advances·2026
Same author

Mania and psychosis following chimeric antigen receptor T-cell therapy: A report of two cases and mechanistic discussion.

Brain, behavior, & immunity - health·2026
Same author

A Behavioral Intervention to Improve Symptoms After Hematopoietic Cell Transplantation.

Journal of pain and symptom management·2026
Same journal

TLR7/8 agonist 3M-052 formulated in micelles induces local type I IFN response and antiviral immunity in zebrafish larvae.

Frontiers in immunology·2026
Same journal

HLA-DRB1*15:01 drives sex- and age-dependent microglial immune phenotypes and neuroimmune signaling.

Frontiers in immunology·2026
Same journal

Gut microbiota transfer from autoimmune dry eye mice imprints stereotypic B cell receptor repertoires in the lacrimal gland and induces disease.

Frontiers in immunology·2026
Same journal

Exosomal microRNAs in colorectal cancer communication networks: implications for metastasis, therapy resistance, and precision medicine.

Frontiers in immunology·2026
Same journal

TMEM160 promotes hepatocellular carcinoma cell proliferation, invasion, and immune evasion by regulating the VEGFA/PI3K/AKT signaling axis.

Frontiers in immunology·2026
Same journal

Nurr1 deficiency orchestrates a coupled liver-gut pathological axis revealed by multi-omics and deep-learning histopathology.

Frontiers in immunology·2026
See all related articles
This summary is machine-generated.

Chimeric antigen receptor T-cell (CAR-T) therapy response is not predicted by initial product function. However, specific CAR-T cell kinetic properties, like responsiveness and cooperativity, correlate with durable responses and predict disease relapse.

Area of Science:

  • Immunology
  • Pharmacology
  • Computational Biology

Background:

  • Chimeric antigen receptor T-cell (CAR-T) therapy effectiveness is influenced by complex CAR-T cell dynamics, including cytotoxicity and proliferation.
  • Patient-specific CAR-T cell product functionality, characterized by distinct cell populations, plays a crucial role in therapeutic outcomes.
  • Understanding these dynamics is key to predicting individual patient responses to CAR-T therapy.

Purpose of the Study:

  • To investigate whether product-specific CAR-T cell parameters can predict individual patient responses to CAR-T therapy.
  • To elucidate the relationship between CAR-T cell kinetics and clinical outcomes using an in vitro assay-based model.
  • To identify specific CAR-T cell functional parameters that correlate with durable responses and disease relapse.
Keywords:
CAR-T cell cytotoxicity kineticsCAR-T cellsCAR-T cellular differentiationCAR-T therapychimeric antigen receptorcomputational modelingmathematical modeling

Related Experiment Videos

Last Updated: May 31, 2026

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

Main Methods:

  • An ordinary differential equation (ODE)-based pharmacokinetic (PK) and pharmacodynamic (PD) model was employed to characterize CAR-T cell functional parameters.
  • Model parameters were derived from in vitro assays performed on individual patient CAR-T products from clinical trial NCT04186520.
  • The study analyzed correlations between estimated model parameters and patient responses at 28, 90, and 180 days post-treatment.

Main Results:

  • Significant variability in in vitro cytotoxicity kinetics and estimated model parameters was observed between CAR-T cell products.
  • These initial product-specific parameters did not predict early (28-day) or late (90-day) therapeutic responses across the patient cohort.
  • Increased CAR-T cell responsiveness to tumor cytotoxicity and CAR-T cell cooperativity were correlated with durable therapy responses (no relapse through 180 days), particularly in diffuse large B-cell lymphoma (DLBCL) patients.

Conclusions:

  • Pre-treatment CAR-T cell functional parameters, while variable, do not predict initial therapeutic responses.
  • Initial CAR-T product kinetic parameters can vary widely yet still lead to therapeutic success.
  • Specific kinetic properties of the initial CAR-T product may predict the likelihood of disease relapse, highlighting potential biomarkers for long-term efficacy.